Vyne Cost Of Revenue vs Revenue Per Share Analysis

VYNE Stock

USD 2.89 0.06 2.03%

Vyne Therapeutics financial indicator trend analysis is much more than just breaking down Vyne Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vyne Therapeutics is a good investment. Please check the relationship between Vyne Therapeutics Cost Of Revenue and its Revenue Per Share accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vyne Therapeutics Cost Of Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Vyne Therapeutics' Cost Of Revenue and Revenue Per Share is -0.34. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Vyne Therapeutics, assuming nothing else is changed. The correlation between historical values of Vyne Therapeutics' Cost Of Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Vyne Therapeutics are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Cost Of Revenue i.e., Vyne Therapeutics' Cost Of Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

-0.34

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Vyne Therapeutics income statement and represents the costs associated with goods and services Vyne Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from Vyne Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.At present, Vyne Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.23, whereas Issuance Of Capital Stock is forecasted to decline to about 347.7 K.

	2021	2022	2023	2024 (projected)
Gross Profit	11.4M	477K	424K	402.8K
Total Revenue	14.8M	477K	424K	402.8K

Gross Profit Total Revenue

Vyne Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Net Receivables	Short Term Investments
Total Assets		0.53	0.58	0.82	-0.02	-0.37	0.54	0.21	0.93	0.59	0.35	-0.52	0.38	0.38	-0.46	0.99	-0.23	0.68	-0.52	0.38	0.44	-0.74	0.3	0.34	0.14	0.64
Other Current Liab	0.53		0.9	0.56	0.06	-0.8	0.79	0.38	0.22	0.82	0.39	-0.63	0.79	0.77	-0.45	0.49	0.2	0.37	-0.64	0.73	0.81	-0.47	0.96	0.93	0.82	-0.24
Total Current Liabilities	0.58	0.9		0.55	0.29	-0.74	0.95	0.13	0.28	0.79	0.33	-0.5	0.81	0.73	-0.38	0.53	0.1	0.59	-0.8	0.76	0.75	-0.65	0.86	0.85	0.63	-0.14
Total Stockholder Equity	0.82	0.56	0.55		-0.23	-0.61	0.55	0.3	0.76	0.75	0.58	-0.89	0.46	0.65	-0.88	0.82	0.05	0.46	-0.62	0.28	0.68	-0.75	0.39	0.45	0.15	0.5
Net Debt	-0.02	0.06	0.29	-0.23		-0.15	0.19	-0.79	-0.15	0.06	0.11	0.31	0.24	0.13	0.36	-0.11	0.06	0.37	-0.32	0.24	0.12	-0.18	0.13	0.18	0.13	-0.05
Retained Earnings	-0.37	-0.8	-0.74	-0.61	-0.15		-0.65	-0.08	-0.14	-0.88	-0.79	0.75	-0.81	-0.99	0.63	-0.34	-0.39	-0.43	0.82	-0.44	-0.99	0.62	-0.84	-0.88	-0.6	0.11
Accounts Payable	0.54	0.79	0.95	0.55	0.19	-0.65		0.09	0.27	0.71	0.25	-0.49	0.76	0.64	-0.41	0.5	0.03	0.57	-0.73	0.59	0.64	-0.65	0.76	0.71	0.45	-0.1
Cash	0.21	0.38	0.13	0.3	-0.79	-0.08	0.09		0.17	0.17	-0.06	-0.36	-0.04	0.1	-0.31	0.27	-0.12	-0.28	0.09	0.36	0.13	0.15	0.31	0.26	0.42	-0.15
Cash And Short Term Investments	0.93	0.22	0.28	0.76	-0.15	-0.14	0.27	0.17		0.39	0.28	-0.42	0.15	0.17	-0.42	0.96	-0.27	0.61	-0.35	0.1	0.22	-0.67	-0.03	0.04	-0.17	0.83
Common Stock Total Equity	0.59	0.82	0.79	0.75	0.06	-0.88	0.71	0.17	0.39		0.56	-0.8	0.78	0.86	-0.72	0.57	0.35	0.47	-0.86	0.55	0.87	-0.75	0.77	0.84	0.51	-0.03
Common Stock Shares Outstanding	0.35	0.39	0.33	0.58	0.11	-0.79	0.25	-0.06	0.28	0.56		-0.62	0.4	0.82	-0.55	0.34	0.09	0.37	-0.58	0.06	0.82	-0.49	0.41	0.52	0.29	0.33
Non Current Liabilities Total	-0.52	-0.63	-0.5	-0.89	0.31	0.75	-0.49	-0.36	-0.42	-0.8	-0.62		-0.56	-0.78	0.96	-0.52	-0.34	-0.19	0.57	-0.23	-0.78	0.57	-0.55	-0.57	-0.31	-0.14
Other Current Assets	0.38	0.79	0.81	0.46	0.24	-0.81	0.76	-0.04	0.15	0.78	0.4	-0.56		0.77	-0.41	0.34	0.57	0.64	-0.77	0.39	0.78	-0.71	0.77	0.74	0.44	-0.18
Other Stockholder Equity	0.38	0.77	0.73	0.65	0.13	-0.99	0.64	0.1	0.17	0.86	0.82	-0.78	0.77		-0.68	0.35	0.35	0.42	-0.82	0.43	0.99	-0.62	0.81	0.86	0.58	-0.06
Total Liab	-0.46	-0.45	-0.38	-0.88	0.36	0.63	-0.41	-0.31	-0.42	-0.72	-0.55	0.96	-0.41	-0.68		-0.47	-0.3	-0.13	0.54	-0.14	-0.66	0.56	-0.37	-0.42	-0.12	-0.2
Total Current Assets	0.99	0.49	0.53	0.82	-0.11	-0.34	0.5	0.27	0.96	0.57	0.34	-0.52	0.34	0.35	-0.47		-0.23	0.66	-0.5	0.34	0.41	-0.73	0.25	0.3	0.09	0.66
Common Stock	-0.23	0.2	0.1	0.05	0.06	-0.39	0.03	-0.12	-0.27	0.35	0.09	-0.34	0.57	0.35	-0.3	-0.23		0.07	-0.33	0.0	0.33	-0.25	0.25	0.23	0.06	-0.37
Other Liab	0.68	0.37	0.59	0.46	0.37	-0.43	0.57	-0.28	0.61	0.47	0.37	-0.19	0.64	0.42	-0.13	0.66	0.07		-0.71	0.2	0.44	-0.87	0.26	0.29	-0.05	0.49
Net Tangible Assets	-0.52	-0.64	-0.8	-0.62	-0.32	0.82	-0.73	0.09	-0.35	-0.86	-0.58	0.57	-0.77	-0.82	0.54	-0.5	-0.33	-0.71		-0.54	-0.81	0.86	-0.64	-0.73	-0.33	-0.07
Property Plant And Equipment Net	0.38	0.73	0.76	0.28	0.24	-0.44	0.59	0.36	0.1	0.55	0.06	-0.23	0.39	0.43	-0.14	0.34	0.0	0.2	-0.54		0.46	-0.24	0.72	0.74	0.78	-0.32
Current Deferred Revenue	0.44	0.81	0.75	0.68	0.12	-0.99	0.64	0.13	0.22	0.87	0.82	-0.78	0.78	0.99	-0.66	0.41	0.33	0.44	-0.81	0.46		-0.63	0.83	0.87	0.61	-0.03
Non Current Assets Total	-0.74	-0.47	-0.65	-0.75	-0.18	0.62	-0.65	0.15	-0.67	-0.75	-0.49	0.57	-0.71	-0.62	0.56	-0.73	-0.25	-0.87	0.86	-0.24	-0.63		-0.35	-0.42	0.03	-0.45
Non Currrent Assets Other	0.3	0.96	0.86	0.39	0.13	-0.84	0.76	0.31	-0.03	0.77	0.41	-0.55	0.77	0.81	-0.37	0.25	0.25	0.26	-0.64	0.72	0.83	-0.35		0.97	0.88	-0.44
Other Assets	0.34	0.93	0.85	0.45	0.18	-0.88	0.71	0.26	0.04	0.84	0.52	-0.57	0.74	0.86	-0.42	0.3	0.23	0.29	-0.73	0.74	0.87	-0.42	0.97		0.87	-0.36
Net Receivables	0.14	0.82	0.63	0.15	0.13	-0.6	0.45	0.42	-0.17	0.51	0.29	-0.31	0.44	0.58	-0.12	0.09	0.06	-0.05	-0.33	0.78	0.61	0.03	0.88	0.87		-0.52
Short Term Investments	0.64	-0.24	-0.14	0.5	-0.05	0.11	-0.1	-0.15	0.83	-0.03	0.33	-0.14	-0.18	-0.06	-0.2	0.66	-0.37	0.49	-0.07	-0.32	-0.03	-0.45	-0.44	-0.36	-0.52

Click cells to compare fundamentals

Vyne Therapeutics Account Relationship Matchups

Vyne Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	79.2M	93.7M	67.0M	40.8M	97.7M	82.0M
Other Current Liab	485K	15.2M	11.2M	7.0M	5.6M	5.6M
Total Current Liabilities	10.7M	21.5M	18.4M	9.3M	7.5M	10.9M
Total Stockholder Equity	68.5M	37.5M	48.6M	31.2M	88.7M	93.2M
Net Debt	(30.1M)	(22.8M)	(41.9M)	(31.3M)	(30.4M)	(31.9M)
Retained Earnings	(184.3M)	(566.2M)	(639.5M)	(662.7M)	(691.3M)	(656.8M)
Accounts Payable	3.8M	4.8M	6.5M	2.4M	1.7M	3.3M
Cash	30.8M	57.6M	42.3M	30.9M	30.7M	36.6M
Cash And Short Term Investments	136.3M	76.9M	58.6M	42.3M	93.3M	70.3M
Common Stock Shares Outstanding	471.4K	1.8M	2.9M	3.2M	10.3M	10.8M
Liabilities And Stockholders Equity	79.2M	93.7M	67.0M	40.8M	97.7M	82.0M
Non Current Liabilities Total	34.3M	34.8M	6.9M	211K	1.4M	1.3M
Other Current Assets	1.4M	4.6M	6.1M	7.2M	2.7M	3.6M
Other Stockholder Equity	252.8M	603.7M	688.2M	692.3M	780.0M	819.0M
Total Liab	10.7M	56.2M	18.4M	9.6M	9.0M	8.5M
Total Current Assets	78.3M	87.3M	63.2M	38.3M	96.0M	78.4M
Other Liab	1.4M	1.1M	880K	769K	884.4K	997.5K
Net Tangible Assets	17.6M	37.5M	48.6M	31.2M	28.1M	48.6M
Property Plant And Equipment Net	769K	2.1M	354K	282K	207K	196.7K
Non Current Assets Total	842K	6.5M	3.9M	2.5M	1.7M	2.9M
Non Currrent Assets Other	73K	4.3M	3.5M	2.2M	1.5M	1.6M
Other Assets	744K	4.9M	3.5M	2.5M	2.9M	1.9M
Net Receivables	135K	15.8M	7.6M	5.2M	5.9M	5.3M
Short Term Investments	86.7M	46.2M	1.0M	0.0	62.6M	65.8M
Property Plant And Equipment Gross	98K	2.1M	354K	0.0	207K	412.2K
Accumulated Other Comprehensive Income	(51K)	(96K)	24K	26K	29.9K	31.4K
Non Current Liabilities Other	22K	7K	457K	1.3M	1.5M	1.6M
Property Plant Equipment	2.2M	4.6M	2.1M	354K	318.6K	302.7K
Net Invested Capital	68.5M	70.7M	48.6M	31.2M	88.7M	59.9M
Net Working Capital	67.7M	65.8M	44.8M	28.9M	88.4M	55.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:

How To Invest In Vyne

Details

Is Vyne Stock a good investment?

Details

What is Vyne Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.72

Revenue Per Share

0.016

Quarterly Revenue Growth

0.467

Return On Assets

(0.35)

Return On Equity

(0.60)

The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vyne Cost Of Revenue vs Revenue Per Share Analysis

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Revenue Per Share

Vyne Therapeutics fundamental ratios Correlations

Vyne Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vyne Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Current Deferred Revenue	+ 0.99	Other Stockholder Equity
Other Assets	+ 0.97	Non Currrent Assets Other
Non Currrent Assets Other	+ 0.96	Other Current Liab
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total

Current Deferred Revenue	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Non Current Liabilities Total	- 0.89	Total Stockholder Equity
Other Assets	- 0.88	Retained Earnings
Common Stock Total Equity	- 0.88	Retained Earnings
Total Liab	- 0.88	Total Stockholder Equity